Skip to main content
. Author manuscript; available in PMC: 2011 Jan 1.
Published in final edited form as: Expert Opin Drug Metab Toxicol. 2010 Jan;6(1):55–68. doi: 10.1517/17425250903393752

Figure 2.

Figure 2

Efavirenz concentration-time profile in three healthy volunteers in the absence (close circles) and presence of rifampin (open circles). The effect of rifampin co-administration varied from a reduction in efavirenz area under the curve by 100% (A) to an intermediate of a reduction by 42% (B) to an increase by 56% (C).